The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure
Open accessAbstract
BACKGROUND: Sudden death from cardiac causes remains a leading cause of death among patients with congestive heart failure (CHF). Treatment with amiodarone or an implantable cardioverter-defibrillator (ICD) has been proposed to improve the prognosis in such patients. METHODS: We randomly assigned 2521 patients with New York Heart Association (NYHA) class II or III CHF and a left ventricular ejection fraction (LVEF) of 35 percent or less to conventional therapy for CHF plus placebo (847 patients), conventional therapy plus amiodarone (845 patients), or conventional therapy plus a conservatively programmed, shock-only, single-lead ICD (829 patients). Placebo and amiodarone were administered in a double-blind fashion. The primary end point was death from any cause. RESULTS: The median LVEF in patients was 25 percent; 70 percent were in NYHA class II, and 30 percent were in class III CHF. The cause of CHF was ischemic in 52 percent and nonischemic in 48 percent. The median follow-up was 45.5 months. There were 244 deaths (29 percent) in the placebo group, 240 (28 percent) in the amiodarone group, and 182 (22 percent) in the ICD group. As compared with placebo, amiodarone was associated with a similar risk of death (hazard ratio, 1.06; 97.5 percent confidence interval, 0.86 to 1.30; P=0.53) and ICD therapy was associated with a decreased risk of death of 23 percent (0.77; 97.5 percent confidence interval, 0.62 to 0.96; P=0.007) and an absolute decrease in mortality of 7.2 percentage points after five years in the overall population. Results did not vary according to either ischemic or nonischemic causes of CHF, but they did vary according to the NYHA class. CONCLUSIONS: In patients with NYHA class II or III CHF and LVEF of 35 percent or less, amiodarone has no favorable effect on survival, whereas single-lead, shock-only ICD therapy reduces overall mortality by 23 percent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In studies, from 7.5% of primary prevention patients 22 to 48% of those with a history of ventricular arrhythmia 23 received a shock for any reason in a year.”
From Managing with pacemakers and implantable cardioverter defibrillators (2013) · cites this paper as [22]
In the citing paper
“ICD treatment led to a significant relative risk reduction in death and in subgroup analysis, there were no interactions with T2DM.”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [165]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
The Statistical Analysis of Failure Time Data.
Aitkin, M. A., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,875
Moss, A. J., Zaręba, W., Hall, W. J., Klein, H., Wilber, D. J., Cannom, D. S., Daubert, J. P., Higgins, S. L., Brown, M. W., & Andrews, M. L. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013474 · Cited by 6,885
Moss, A. J., Hall, W. J., Cannom, D. S., Daubert, J. P., Higgins, S. L., Klein, H., Levine, J. H., Saksena, S., Waldo, A. L., Wilber, D., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352601 · Cited by 4,165
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
The AVID Investigators (1997) · New England Journal of Medicine · doi:10.1056/nejm199711273372202 · Cited by 3,221
The Statistical Analysis of Failure Time Data
Kalbfleisch, J. D., & Prentice, R. L. (2002) · Wiley Series in Probability and Statistics · doi:10.1002/9781118032985 · Cited by 3,219
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated Cardiomyopathy
Kadish, A. H., Dyer, A. R., Daubert, J. P., Quigg, R. J., Estes, N. A. M., Anderson, K. P., Calkins, H. G., Hoch, D., Goldberger, J. J., Shalaby, A. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033088 · Cited by 2,078
The DAVID Trial Investigators* (2002) · JAMA · doi:10.1001/jama.288.24.3115 · Cited by 2,056
Canadian Implantable Defibrillator Study (CIDS)
Connolly, S. J., Gent, M., Roberts, R. S., Dorian, P., Roy, D., Sheldon, R. S., Mitchell, L. B., Green, M. S., Klein, G. J., & O’Brien, B. (2000) · Circulation · doi:10.1161/01.cir.101.11.1297 · Cited by 1,601
Amiodarone in Patients with Congestive Heart Failure and Asymptomatic Ventricular Arrhythmia
Singh, S. N., Fletcher, R. D., Fisher, S. G., Singh, B. N., Lewis, H. D., DEEDWANIA, P. C., Massie, B. M., Colling, C. L., & Lazzeri, D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199507133330201 · Cited by 1,217
Julian, D. G., CAMM, A. J., Frangin, G., Janse, M. J., Munoz, A., Pj, S., & Simon, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)09145-3 · Cited by 1,100
Bigger, J. T. (1997) · New England Journal of Medicine · doi:10.1056/nejm199711273372201 · Cited by 1,010
Cairns, J. A., Connolly, S. J., Roberts, R. E., & Gent, M. (1997) · The Lancet · doi:10.1016/s0140-6736(96)08171-8 · Cited by 949
Randomised trial of low-dose amiodarone in severe congestive heart failure
Doval, H., Nul, D. R., Grancelli, H., Perrone, S. V., Bortman, G., & Curiel, R. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91895-3 · Cited by 913
Strickberger, S. A., Hummel, J. D., Bartlett, T. G., Frumin, H., Schuger, C. D., Beau, S. L., Bitar, C., & Morady, F. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00297-3 · Cited by 588
The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial
Wilkoff, B. L., & DAVID Trial Investigators (2003) · Pacing and Clinical Electrophysiology · doi:10.1046/j.1460-9592.2003.t01-2-00231_5.x · Cited by 36
Flagged first, then by citations
Research works printed but not linked: 1
- 10.2307/2281868 · DOI · Paper page
Cited by
Sorted by citations
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2021) · PubMed · doi:10.1093/eurheartj/ehab670 · Cited by 20,604
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Metadata
- Authors
- Bardy, G. H., Lee, K. L., Mark, D. B., Poole, J. E., Packer, D. L., Boineau, R., Domanski, M., Troutman, C., Anderson, J., Johnson, G., McNulty, S. E., Clapp-Channing, N., Davidson-Ray, L. D., Fraulo, E. S., Fishbein, D. P., Luceri, R. M., & Ip, J. H.
- Affiliations
- The Seattle Institute for Cardiac Research (US)
- Duke University (US)
- University of Washington (US)
- Mayo Clinic (US)
- National Heart, Lung, and Blood Institute (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-01-20
- Volume
- 352
- Issue
- 3
- Pages
- 225-237
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2075175982
- Semantic Scholar
- cf04075b17dbae3fc6bc9a3a2f9673f9fad192ea
- Cited by
- 6,552
- References
- 20
- Citations by year
- 2026: 126 · 2025: 170 · 2024: 173 · 2023: 186 · 2022: 231 · 2021: 236 · 2020: 261 · 2019: 285 · 2018: 287 · 2017: 394 · 2016: 326 · 2015: 355 · 2014: 335 · 2013: 369 · 2012: 376
- FWCI
- 292.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (UO1 HL55297, UO1 HL55496, UO1 HL55766, U01HL055297, U01HL055766, U01HL055496)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac pacing and defibrillation studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
- Keywords
- amiodarone, implantable cardioverter-defibrillator, congestive heart failure, sudden cardiac death, mortality, left ventricular ejection fraction, NYHA functional class, antiarrhythmic therapy
- MeSH terms
- Aged, Amiodarone, Anti-Arrhythmia Agents, Cause of Death, Female, Heart Failure, Humans, Male, Middle Aged, Risk, Stroke Volume, Survival Analysis, Death, Sudden, Cardiac, Defibrillators, Implantable, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
